Biotech company struggling to survive after flop with Teva
The biotech company Active Biotech that together with Teva developed a failing sclerosis drug is currently counting on a property sale to raise capital for the company’s survival.
BY MIKKEL AABENHUS HEMMINGSEN
The publicly listed Swedish company Active Biotech is living on borrowed time if the company does not manage to raise money as soon as possible.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
